This site is intended for US Healthcare Professionals.

Overall survival in myelodysplastic syndromes (MDS)

Overall survival in myelodysplastic syndromes (MDS)

In myelodysplastic syndromes (MDS), anemia and transfusion burden critically impact overall survival (OS)1-3

  • Patients with lower-risk MDS experience significant mortality4
  • Severe anemia in MDS shortens patients’ lives and is associated with a more rapid evolution to acute myeloid leukemia (AML)1
  • Transfusion dependence also contributes to poorer OS1-3

Lower-risk MDS can take years away from patients’ lives4*

Calendar icon

<5 years

Median OS

*Analysis of 2396 patients from a prospective, noninterventional, longitudinal registry from January 2008 to December 2018, followed up to December 2019.4

Anemia and transfusions may negatively impact patients' lives1-3

Hgb levels 8-<10 g/dL are associated with a ~50% shorter median OS than Hgb levels ≥10 g/dL1†

Analysis based on combined international databases of 7012 patients with primary untreated MDS.1

Transfusion independence is associated with a 59% decreased risk of death for patients2‡

[HR 0.41; 95% credible interval (CrI) 0.29-0.56]

According to a meta-analysis of 89 publications on the association between OS and transfusion independence in patients with MDS.2

Actively manage Hgb levels and transfusion burden to improve survival in MDS1-3


1. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. 2. Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systemic literature review and meta-anlaysis. Acta Haematol. 2016;136(1):23-42. 3. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91(12):1588-1590. 4. Madry K, Lis K, Fenaux P, et al. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS registry. Br J Haematol. 2023;200(4):451-461.